Introduction {#Sec1}
============

Hematopoietic stem cell transplants (HSCT) recipients are at increased risk for respiratory viral infections and their associated complications \[[@CR1]\]. With the recent availability of multiplexed PCR assays that can rapidly detect a variety of respiratory viral pathogens, the opportunity exists to better understand the epidemiology and clinical impact of the different respiratory viruses in this patient population. Although the impact of influenza, rhinovirus, respiratory syncytial virus (RSV), and parainfluenza have been well characterized in HSCT recipients, little is known about the epidemiology and clinical significance of human coronavirus (HCoV) infection in these vulnerable patients.

The four most common HCoV serotypes are OC43, HKU1, NL63, and 229E \[[@CR2], [@CR3]\]. These four strains most commonly cause classic "common cold" infectious symptoms in immunocompetent individuals \[[@CR3]\]. In HSCT recipients, however, the incidence of post-transplant infection, symptomatology, risk of and risk factors for progression to lower respiratory tract infection (LRTI) and respiratory failure are largely unknown. Furthermore, the clinical and microbiological risk factors for clinical deterioration in this population are also unknown. This information would assist clinicians in identifying HSCT recipients with HCoV infection who have the highest risk of clinical deterioration and thus warrant closer monitoring. Furthermore, these data would inform and optimize the design of future clinical trials of novel anti-HCoV therapies \[[@CR4]\]. Therefore, we conducted a retrospective observational cohort study of HSCT recipients at our institution who were infected with HCoV. We report the incidence, epidemiology, and outcomes of these patients, as well as the risk factors associated with progression to proven or probable LRTI.

Methods {#Sec2}
=======

Study population and data collection {#Sec3}
------------------------------------

All HSCT recipients at NewYork Presbyterian Hospital-Weill Cornell Medical Center with new respiratory symptoms had a nasopharyngeal (NP) swab collected as a part of routine clinical care. Providers did not routinely swab asymptomatic patients or patients with fever in the absence of respiratory symptoms. The NP swabs were tested using the FilmArray® Respiratory Panel (BioFire Diagnostics, LLC., Salt Lake City, UT, USA), a multiplexed PCR assay that rapidly detects 17 respiratory viruses, including the four main coronavirus serotypes. We retrospectively identified all respiratory viral infections that occurred in patients transplanted between May 2013 and July 2017. We calculated the cumulative incidence of post-transplant HCoV infection in this cohort and compared it to that of other respiratory viruses.

We then evaluated the clinical presentation, rate and risk factors for progression to LRTI, and duration of viral shedding in patients infected with HCoV. Only the first post-transplant episode of HCoV infection was evaluated. Demographic and clinical data were collected retrospectively from all patients in this cohort using the institution's electronic medical record and HSCT database. This study was approved by the Institutional Review Board at Weill Cornell Medicine (IRB \# 1805019257).

Definitions {#Sec4}
-----------

URI was defined as exhibiting at least one of the following symptoms: cough, coryza, sore throat, or shortness of breath in combination with a clinician's judgment that the aforementioned symptoms were indicative of a respiratory tract infection, and a positive identification of HCoV on NP swab. Probable LRTI was defined as having symptoms of pathologic sputum production or hypoxia in the setting of a new pulmonary infiltrate on radiograph or CT scan. Proven LRTI was defined as when criteria for probable LRTI were met in addition to detection of HCoV in bronchoalveolar lavage (BAL) fluid. These definitions are consistent with guidelines for the diagnosis of respiratory virus infections in patients with leukemia and HSCT recipients, as well as definitions used in prior studies of HCoV infections in HSCT recipients (3,13). Respiratory failure was defined as the need for mechanical ventilation within 30 days of isolating the virus or respiratory failure listed as the primary cause of death within 30 days of virus detection.

Persistent viral shedding was defined as persistent HCoV detection on NP swab ≥21 days after the initial diagnosis, allowing no more than one negative sample or more than 4 weeks between any two consecutive positive samples. Total duration of viral shedding was calculated from the first positive to the final positive samples (12,14). Of note, follow-up NP swabs were not routinely collected at our institution unless patients developed new, worsening, or recurrent respiratory symptoms.

Statistical analyses {#Sec5}
--------------------

Statistical analyses were performed using STATA, version 15.0 (StataCorp LLC, College Station, TX). We evaluated factors associated with the development of proven and probable LRTI by univariate analysis using Chi-square or Fisher's exact test, as appropriate, to compare categorical variables, and the Wilcoxon rank-sum test to compare continuous variables. We considered a *P* value ≤0.05 to be significant. Variables with *P* values ≤0.1 were initially entered into a multivariable logistic regression model and a backward stepwise selection process was applied until only variables with *P* \< 0.05 remained in the final model. Similar univariate and multivariate analyses were also performed to identify factors associated with prolonged viral shedding.

Results {#Sec6}
=======

Incidence and seasonality of HCoV {#Sec7}
---------------------------------

There were 678 patients who underwent a HSCT between May 2013 and June 2017, of which 112 (17%) had a post-transplant HCoV infection, with a median follow-up period of 758 days. HCoV was the fourth most common respiratory viral infection in this population, more common than adenovirus (4%), human metapneumovirus (6%), and RSV (13%), but less common than rhinovirus/enterovirus (29%), parainfluenza (26%), and influenza (20%; Fig. [1a](#Fig1){ref-type="fig"}). Coronavirus OC43 was the most common HCoV strain detected (40%), followed by NL63 (20%), HKU1 (19%), and 229E (14%; Fig. [1b](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). Eight patients (7%) were infected with two strains of HCoV: 4 patients with HKU1 and OC43, 2 patients with HKU1 and 229E, 1 patient with NL63 and OC43, and 1 patient with NL63 and 229E. Figure [2](#Fig2){ref-type="fig"} reflects the seasonality of HCoV infection in the study population. The incidence of HCoV infection was highest in the months of December through March for all serotypes. The prevalence and seasonality of serotypes did not alter significantly over the study period.Fig. 1**a** Cumulative incidence of post-transplant respiratory viral infection in 678 hematopoietic stem cell transplant (HSCT) recipients from May 2013 through June 2017. Incidence is expressed as a percent of all HSCT recipients infected. **b** Infection by coronavirus (HCoV) serotype expressed as a percentage of total HCoV infections in 112 patients transplanted between May 2013 and July 2017. The four serotypes were OC43, NL63, HKU1, and 229E. Multiple denotes patients infected with 2 strains: 4 patients had HKU1 and OC43, 2 patients had HKU1 and 229E, 1 patient had NL63 and OC43, and 1 patient had NL63 and 229ETable 1Baseline characteristics of HSCT recipients with HCoV infectionBaseline characteristicsTotal (*n* = 112)URTI (*n* = 78)Probable LRTI (*n* = 27)Proven LRTI (*n* = 7)*P* value (URI vs. proven or probable LRTI)Median age, years54 (42--63)50 (38--63)58 (52--64)62 (57--65)0.009Female sex52 (46)35 (45)15 (56)2(29)0.62Coronavirus type  OC4345 (40)35 (45)8 (30)2 (29)0.13  NL6322 (20)15 (19)6 (22)1 (14)0.87  HKU121 (19)14 (18)4 (15)3 (43)0.74  229E16 (14)10 (13)5 (19)1 (14)0.56  Multiple serotypes8 (7)4 (5)4 (15)0 (0)0.24Underlying malignancy  AML39 (35)25 (32)11 (41)3 (43)0.35  MM21 (19)15 (19)3 (11)3 (43)0.84  NHL16 (14)12 (15)4 (15)0 (0)0.77  ALL15 (13)11 (14)3 (11)1 (14)1.00  MDS/MPN12 (11)8 (10)4 (15)0 (0)0.75  CML4 (4)3 (4)1 (4)0 (0)1.00  HL3 (3)3 (4)0 (0)0 (0)0.56  Other2 (2)1 (1)1 (0)0 (0)0.52 Autologous HSCT28 (25)21 (27)5 (19)2 (29)0.48Allogeneic HSCT  MUD28 (25)17 (22)9 (33)2 (29)0.24  Haplo/cord28 (25)21 (27)5 (19)2 (29)0.48  MRD22 (20)18 (23)3 (11)1 (14)0.17  Double cord3 (3)1 (1)2 (7)0 (0)0.22  Other3 (3)0 (0)3 (11)0 (0)0.026Comorbidities  COPD3 (3)3 (4)0 (0)0 (0)0.55  Asthma6 (5)3(4)1 (4)2 (29)0.37  Tobacco use (prior or current)41 (37)30 (38)10 (37)1 (14)0.54  Diabetes mellitus13 (12)8 (10)2 (7)3 (43)0.53  CHF10 (9)5 (6)4 (15)1 (14)0.17 GVHD18 (16)8 (10)8 (30)2 (29)0.01 Corticosteroid use31 (28)16 (21)10 (37)5 (71)0.01 Neutropenia15 (13)8 (10)5 (19)2 (29)0.23 Lymphopenia31 (28)20 (26)8 (30)3 (43)0.47 Albumin, g/dL3.5 (3--4)3.8 (3.2--4.1)3.1 (2.9--3.5)2.3 (1.9--2.8)\<0.001 IgG level, mg/dL760 (447--1110)788 (460--1090)686 (391--1330)241 (141--598)0.19 Alemtuzumab use in prior 1 year49 (44)34 (30)12 (44)3 (43)0.96 Treatment with IVIG9 (8)5 (6)2 (7)2 (29)0.45 ATG use in previous year29 (26)20 (18)7 (26)2 (29)0.8 Respiratory co-infection35 (31)15 (19)15 (56)5 (71)\<0.001 Concurrent bacteremia14 (13)6 (8)7 (26)1 (14)0.029 Inpatient status39 (35)18 (23)17 (63)4 (57)\<0.001All values are expressed as no. (%) or median (interquartile range)*HSCT* hematopoietic stem cell transplant, *HCoV* human coronavirus, *URTI* upper respiratory tract infection, *LRTI* lower respiratory tract infection, *AML* acute myeloid leukemia, *MM* multiple myeloma, *NHL* non-Hodgkin lymphoma, *ALL* acute lymphoblastic leukemia, *MDS/MPN* myelodysplastic/myeloproliferative neoplasm, *CML* chronic myeloid leukemia, *HL* Hodgkin lymphoma, *MUD* matched unrelated donor, *MRD* matched related donor, *COPD* chronic obstructive pulmonary disease, *CHF* congestive heart failure, *GVHD* graft-versus-host disease, *IgG* immunoglobulin G, *IVIG* intravenous immunoglobulin, *ATG* anti-thymocyte globulinFig. 2Seasonality of human coronavirus (HCoV) infections in hematopoietic stem cell transplant (HSCT) recipients, by HCoV serotype from May 2013 through June 2017. HCoV infection was more common in the winter months (December through March)

Patient characteristics {#Sec8}
-----------------------

Table [1](#Tab1){ref-type="table"} outlines the baseline characteristics of the 112 patients with post-transplant HCoV infection. Fifty-two (46%) patients were female, and the median age at infection onset was 54 years. Acute myeloid leukemia (AML; 35%) was the most common hematologic malignancy. The median time from transplant to HCoV infection was 168 days (interquartile range \[IQR\] 70--304). Thirty-one (28%) were taking corticosteroids at the time of HCoV infection. Thirty-five patients (31%) had co-infection with another respiratory pathogen, and 14 (13%) had bacteremia. Additionally, 15 patients (13%) were neutropenic (≤500 cells/μL), 31 (28%) were lymphopenic (≤200 cells/μL), and 39 (35%) were inpatients at the time of diagnosis.

Clinical characteristics of post-transplant HCoV infection {#Sec9}
----------------------------------------------------------

Cough and rhinorrhea were the most common presenting symptoms, occurring in 65% and 56% of patients, respectively (Table [2](#Tab2){ref-type="table"}). Thirty-two patients (29%) had fever at presentation, 22 (20%) had dyspnea, and 9 (8%) were hypoxic. The clinical features of HCoV infection at the time of presentation did not significantly vary among serotypes.Table 2Clinical features of HCoV infection by serotypeHCoV HKU1 (*n* = 21)HCoV NL63 (*n* = 22)HCoV OC43 (*n* = 45)HCoV 229E (*n* = 16)HCoV Multiple^a^ (*n* = 8)Total (*n* = 112)Clinical feature  Fever6 (29)9 (41)13 (29)3 (19)1 (13)32 (29)  Rhinorrhea12 (57)10 (45)28 (62)10 (63)3 (38)63 (56)  Cough15 (71)14 (64)33 (73)6 (38)5 (63)73 (65)  Productive cough3 (14)6 (27)11 (24)1 (6)3 (38)24 (21)  Dyspnea9 (43)4 (18)6 (13)2 (13)1 (13)22 (20)  Hypoxia3 (14)2 (9)2 (4)1 (6)1 (13)9 (8)Co-infection  Respiratory co-infection8 (38)7 (32)13 (29)3 (19)4 (50)35 (31)  Bacteremia5 (24)3 (14)5 (11)1 (6)0 (0)14 (13)Outcome  LRTI7 (33)7 (32)10 (22)6 (38)4 (50)34 (30)  Intubated within 30 days3 (14)1 (5)4 (9)2 (13)0 (0)10 (9)  Death within 30 days1 (5)1 (5)2 (4)0 (0)0 (0)4 (4)  Death within 90 days3 (14)2 (9)6 (13)1 (6)0 (0)12 (11)All values are reported as no. (%)*HCoV* human coronavirus, *LRTI* lower respiratory tract infection^a^Multiple denotes infection with more than one serotype

Thirty-four patients (30%) developed a proven or probable LRTI within 30 days of diagnosis of HCoV infection. Eleven patients with LRTI symptoms underwent bronchoscopy. Of those patients, 7 had detectable HCoV in the BAL and were therefore considered to have a proven LRTI. Five of those patients had a co-pathogen detected on BAL. Figure [3a, b](#Fig3){ref-type="fig"} demonstrates representative computed tomography (CT) findings in 2 patients with proven HCoV LRTI without a respiratory co-pathogen.Fig. 3**a** A representative CT scan of a patient infected with coronavirus (HCoV) who progressed to proven lower respiratory tract infection (LRTI) without co-infection with a secondary respiratory virus. The CT demonstrates diffuse ground glass opacities, interlobular septal thickening in the airways and bilateral pleural effusions. **b** A representative CT scan of another patient infected with coronavirus (HCoV) who progressed to a proven lower respiratory tract infection (LRTI). The scan demonstrates focal areas of consolidation with air bronchograms and left lingular and left lower lobe ground glass opacities

Fifteen (56%) patients with probable LRTI harbored a respiratory co-pathogen as detected on NP swab (Fig. [4](#Fig4){ref-type="fig"}). Ten (9%) patients required intubation and mechanical ventilation within 30 days of diagnosis of infection. The overall 30-day mortality rate was 4% and the 90-day mortality rate was 11%. Thirty-five patients harbored a respiratory co-pathogen of which 20 progressed to proven or probable LRTI (*P* \< 0.001). In a sub-group analysis, respiratory co-infection in patients with proven or probable LRTI was not significantly associated with respiratory failure (*P* = 0.80), mortality at 30-days (*P* = 1.00), mortality at 90-days (*P* = 1.00), or prolonged HCoV shedding (*P* = 0.97).Fig. 4Respiratory co-pathogens in coronavirus (HCoV)-infected hematopoietic stem cell transplant recipients who progressed to proven or probable lower respiratory tract infection (LRTI)

Factors associated with proven or probable HCoV LRTI {#Sec10}
----------------------------------------------------

Table [3](#Tab3){ref-type="table"} illustrates the clinical and laboratory features associated with proven or probable LRTI in patients infected with HCoV. In univariate analysis, the following variables were associated with proven or probable LRTI: age ≥ 50 years, inpatient status, GVHD, corticosteroid use, and serum albumin ≤ 3.5 g/dL. In multivariate analysis, the following variables remained independently associated with proven or probable LRTI: age ≥ 50, (adjusted odds ratio \[aOR\] 3.63, 95% CI 1.16--11.35; *P* = 0.027), inpatient status (aOR 3.77, 95% CI 1.15--12.41; *P* = 0.03), corticosteroid use (aOR 2.99, 95% CI 1.00--8.88; *P* = 0.049), and serum albumin ≤ 3.5 g/dL (aOR 3.94, 95% CI 1.09--14.22; *P* = 0.036). Of note, infection with HCoV 229E was not associated with progression to proven or probable LRTI in univariate analysis (OR 2.1, 95% CI 0.61--7.20; *P* = 0.24); however, an association was noted on multivariable analysis (OR 5.71, 95% CI 1.15--28.24; *P* = 0.03).Table 3Univariate and multivariate analysis of factors associated with progression to proven or probable LRTI in HSCT recipients with HCoV infectionVariableUnivariable odds ratio (95% CI)Univariable *P* valueMultivariable odds ratio (95% CI)Multivariable *P* valueAge ≥504.27 (1.67--10.97)0.0033.63 (1.16--11.35)0.03Female sex1.23 (0.55--2.75)0.62Coronavirus type  OC43ReferenceReferenceReferenceReference  HKU11.75 (0.56--5.51)0.341.36 (0.32--5.78)0.68  NL631.63 (0.52--5.11)0.41.57 (0.40--6.18)0.52  229E2.10 (0.61--7.20)0.245.71 (1.15--28.24)0.03  Multiple3.4 (0.74--16.56)0.114.02 (0.59--27.60)0.16Inpatient status5.38 (2.26--12.84)\<0.0013.77 (1.15--12.41)0.03Auto HSCT recipient0.70 (0.27--1.86)0.48Asthma or COPD1.16 (0.27--4.94)0.84CHF2.52 (0.68--9.35)0.17Current or prior tobacco use0.77 (0.33--1.80)0.54GVHD3.65 (1.30--10.3)0.015Corticosteroids within 30 days of diagnosis3.06 (1.28--7.32)0.0122.99 (1.00--8.88)0.049Steroids and GVHD4.32 (1.40--13.36)0.011Neutropenia (ANC≤500)2.27 (0.75--6.86)0.15Lymphopenia (ALC\<200)1.39 (0.58--3.34)0.47Serum albumin (\<3.5)7.47 (2.77--20.15)\<0.0013.94 (1.09--14.22)0.04*LRTI* lower respiratory tract infection, *HSCT* hematopoietic stem cell transplant, *HCoV* human coronavirus, *COPD* chronic obstructive pulmonary disease, *CHF* congestive heart failure, *GVHD* graft-versus-host disease, *ANC* absolute neutrophil count, *ALC* absolute lymphocyte count

Persistent viral shedding {#Sec11}
-------------------------

Forty-six (41%) patients had a repeat nasal swab within 4 weeks of their initial infection. The median duration of shedding was 4 weeks, (range 0--30 weeks). Twenty-seven (59%) of those patients had persistent viral shedding beyond 21 days from initial infection. No one coronavirus strain was associated with persistent shedding. Inpatient status at time of infection was the only variable significantly associated with prolonged coronavirus shedding.

Discussion {#Sec12}
==========

Our study addresses the poorly understood clinical significance of HCoV infection in HSCT recipients. We found that HCoV infection is common after HSCT, occurring in approximately one out of 6 HSCT recipients at our medical center. We found that older age, corticosteroid use, hypoalbuminemia, and inpatient status were significantly associated with proven or probable LRTI. Additionally, prolonged viral shedding was detected in 59% of patients who underwent subsequent NP swab.

We are aware of only two previously published reports of the incidence of HCoV infection in adult HSCT recipients, and these reports analyzed fewer than 300 patients in total \[[@CR3], [@CR5]\]. In this study of nearly 700 HSCT recipients, symptomatic HCoV infection occurred in 17% of patients, surpassed in incidence only by rhinovirus/enterovirus, influenza, and parainfluenza infections. This cumulative incidence is consistent with the 11--23% incidence reported in prior studies of HSCT recipients \[[@CR3], [@CR5]\]. The serotype most frequently detected in our population over the duration of the study was OC43, accounting for 40% of all infections, and least common one was 229E (14%). This serotype profile is similar to what has been noted at other institutions in a wide variety of geographical locations \[[@CR2], [@CR3], [@CR6]--[@CR8]\]. Furthermore, all serotypes demonstrated winter seasonality, consistent with prior reports \[[@CR3], [@CR5]\].

Data regarding the severity of HCoV infection in HSCT recipients in previous reports are limited, but our finding that 30% of patients had proven or probable LRTI is compatible with findings from prior studies \[[@CR3], [@CR5]\]. The high rate of proven or probable LRTI in this patient population indicates that HCoV infection may have greater clinical significance and severity in HSCT recipients than previously thought. Like prior studies, co-infection with another respiratory pathogen was common in patients with HCoV \[[@CR2], [@CR3]\]. In fact, 59% of patients with proven or probable LRTI harbored a co-infection with another respiratory pathogen detected on NP swab (*P* \< 0.001). Three potential explanations for this finding are (1) HCoV infection increases susceptibility to infections by other pathogens; (2) co-infection with other respiratory pathogens increases the likelihood of progression to LRTI; or (3) co-infections increase the likelihood of obtaining chest CTs or bronchoscopies, which lead to the detection of LRTI. Importantly, we found that on subgroup analysis of those patients with a proven or probable LRTI, co-infection with another respiratory virus was not associated with respiratory failure, death at 30 days or death at 90 days, indicating that severity of a proven or probable HCoV LRTI is independent of co-infection.

While on univariate analysis none of the strains were significantly associated with proven or probable LRTI, on multivariate analysis, infection with 229E was significantly associated with progression to probable or proven LRTI. The significance of this finding is unclear, but it may indicate that 229E is a more pathogenic strain in HSCT recipients. This distinct association has not been found in other studies \[[@CR2], [@CR5], [@CR9]\]. Further research is needed to examine this relationship.

We found that that age ≥ 50, presence of GVHD, corticosteroid use at the time of HCoV diagnosis, hypoalbuminemia (albumin ≤ 3.5 g/dL), and inpatient status at the time of infection were significantly associated with proven or probable LRTI. These factors may be general indicators of frailty and susceptibility for more severe infection and may highlight individuals in whom to more closely surveille and target treatment interventions in the future. Interestingly, underlying lung disease with COPD or asthma did not appear to be associated with progression to LRTI; however, the number of patients in our study with these comorbidities was limited.

It is well documented in the literature that influenza, RSV, rhinovirus, and parainfluenza viruses are associated with prolonged viral shedding in HSCT recipients, but the persistence of HCoV shedding in HSCT recipients is poorly understood \[[@CR1], [@CR10], [@CR11]\]. While a "test of cure" is not routinely performed at our institution, patients undergo repeat NP swabs for worsening or recurrent symptoms. We found that of patients with follow-up respiratory swabs, 59% had persistent shedding of the virus, defined as shedding for ≥21 days after initial infection. No one serotype was significantly associated with persistent viral shedding, consistent with what Ogimi et al. observed in their HSCT population \[[@CR12]\]. Additionally, the median duration of shedding in our cohort was 4 weeks, as compared to the 3 weeks described by Ogimi et al. \[[@CR12]\]. Milano et al. found that in HSCT recipients with asymptomatic HCoV infection, the median duration of viral shedding was 4 weeks \[[@CR5]\]. It is difficult to compare our cohort to others reported in the literature because (1) we did not screen asymptomatic individuals for infection, and (2) we did not test for persistent infection; repeat NP swab was only obtained for worsening or new respiratory symptoms. While the clinical relevance of prolonged viral shedding remains unclear, understanding the risk factors and duration of shedding has implications for infection control in this highly vulnerable population. Further research is needed to better understand the mechanisms and clinical significance of prolonged HCoV shedding.

This study has limitations. First, because it is retrospective, we may not have captured patients with mild symptoms who were not tested, leading us to underestimate the incidence of HCoV infection. The potential for missing mild cases may have also led us to overestimate the risk of progression to LRTI. However, our center had a policy of collecting NP swabs to assess for respiratory viral infection in all HSCT recipients with new respiratory symptoms during the study period. Second, only 11 patients underwent bronchoscopy, so presence or absence of HCoV in the lower respiratory tract was not discerned in most of the patients. However, given that pneumonia is a clinical diagnosis, we relied on the combination of clinical and radiographic findings to diagnose probable LRTI (13). Last, a test of cure for respiratory viruses is not standard-of-care at our institution. Therefore, only patients who had persistent symptoms or recurrent symptoms at a follow-up visit or during hospitalization underwent repeat NP swab at varying intervals. Thus, our data on persistent HCoV shedding may be underestimated, and prospective studies are needed to further evaluate this.

This is the largest study to date characterizing HCoV infections in HSCT recipients. We demonstrated that HCoV infection in HSCT recipients is common and clinically significant, with nearly one-third of patients progressing to a proven or probable LRTI. We described factors that appear to be associated with progression LRTI, defining a sub-population of HSCT recipients that may benefit from closer monitoring and aggressive supportive care when infected with HCoV. Furthermore, this may represent a population in which to target an HCoV antiviral agent in future clinical trials. Prospective studies on HCoV infection in HSCT recipients are needed to further delineate risk factors for LRTI and prolonged viral shedding.
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